Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting

被引：19
作者：
Buettner, Ralf [1 ]
Morales, Corey [1 ]
Caserta, Enrico [1 ]
Troadec, Estelle [1 ]
Gunes, Emine G. [1 ]
Viola, Domenico [1 ]
Khalife, Jihane [1 ]
Li, Hongzhi [2 ]
Keats, Jonathan J. [3 ]
Christofferson, Austin [3 ]
Wu, Xiwei [4 ]
Synold, Timothy W. [5 ]
Palmer, Joycelynne [2 ]
Sanchez, James F. [1 ]
Pozhitkov, Alexander [2 ]
Vaidehi, Nagarajan [2 ]
Marcucci, Guido [6 ]
Krishnan, Amrita [1 ]
Rosenzweig, Michael A. [1 ]
Pichiorri, Flavia [1 ]
Rosen, Steven T. [1 ]
机构：
[1] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Judy & Bernard Briskin Ctr Multiple Myeloma Res, Hematol Malignancies & Stem Cell Transplantat Ins, 1500 E Duarte Rd, Duarte, CA 91010 USA
[2] City Hope Natl Med Ctr, Dept Computat & Quantitat Med, Duarte, CA USA
[3] Translat Genom Res Inst, Integrated Canc Genom, Phoenix, AZ USA
[4] City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Med, Integrat Genom Core, Duarte, CA USA
[5] City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Biol, Duarte, CA USA
[6] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Gehr Family Ctr Leukemia Res, Hematol Malignancies & Stem Cell Transplantat Ins, Duarte, CA USA
来源：
BLOOD ADVANCES | 2019年 / 3卷 / 07期
基金：
美国国家卫生研究院;
关键词：
MULTIPLE-MYELOMA; KINASE INHIBITOR; IDENTIFICATION; ACTIVATION; PROMOTES; DRUG;
D O I：
10.1182/bloodadvances.2018027227
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1027 / 1032
页数：6
相关论文
共 25 条
  • [1] The survival kinases Akt and Pim as potential pharmacological targets
    Amaravadi, R
    Thompson, CB
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (10) : 2618 - 2624
  • [2] Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity
    Anastassiadis, Theonie
    Deacon, Sean W.
    Devarajan, Karthik
    Ma, Haiching
    Peterson, Jeffrey R.
    [J]. NATURE BIOTECHNOLOGY, 2011, 29 (11) : 1039 - U117
  • [3] Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach
    Baker, Angela
    Braggio, Esteban
    Jacobus, Susanna
    Jung, Sungwon
    Larson, Dirk
    Therneau, Terry
    Dispenzieri, Angela
    Van Wier, Scott A.
    Ahmann, Gregory
    Levy, Joan
    Perkins, Louise
    Kim, Seungchan
    Henderson, Kimberly
    Vesole, David
    Rajkumar, S. Vincent
    Jelinek, Diane F.
    Carpten, John
    Fonseca, Rafael
    [J]. BLOOD, 2013, 121 (16) : 3147 - 3152
  • [4] Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells
    Baumann, Philipp
    Mandl-Weber, Sonja
    Voelkl, Andreas
    Adam, Christian
    Bumeder, Irmgard
    Oduncu, Fuat
    Schmidmaier, Ralf
    [J]. MOLECULAR CANCER THERAPEUTICS, 2009, 8 (02) : 366 - 375
  • [5] Pim kinases in cancer: Diagnostic, prognostic and treatment opportunities
    Blanco-Aparicio, Carmen
    Carnero, Amancio
    [J]. BIOCHEMICAL PHARMACOLOGY, 2013, 85 (05) : 629 - 643
  • [6] Leflunomide: mode of action in the treatment of rheumatoid arthritis
    Breedveld, FC
    Dayer, JM
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2000, 59 (11) : 841 - 849
  • [7] Buettner R, 2017, BLOOD, V130
  • [8] AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies
    Chesi, Marta
    Robbiani, Davide F.
    Sebag, Michael
    Chng, Wee Joo
    Affer, Maurizio
    Tiedemann, Rodger
    Valdez, Riccardo
    Palmer, Stephen E.
    Haas, Stephanie S.
    Stewart, A. Keith
    Fonseca, Rafael
    Kremer, Richard
    Cattoretti, Giorgio
    Bergsagel, P. Leif
    [J]. CANCER CELL, 2008, 13 (02) : 167 - 180
  • [9] Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma
    Chng, W-J
    Huang, G. F.
    Chung, T. H.
    Ng, S. B.
    Gonzalez-Paz, N.
    Troska-Price, T.
    Mulligan, G.
    Chesi, M.
    Bergsagel, P. L.
    Fonseca, R.
    [J]. LEUKEMIA, 2011, 25 (06) : 1026 - 1035
  • [10] The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase
    Davis, JP
    Cain, GA
    Pitts, WJ
    Magolda, RL
    Copeland, RA
    [J]. BIOCHEMISTRY, 1996, 35 (04) : 1270 - 1273
123